한글목차

듀센형 근이영양증 시장 규모는 최근 현저한 성장을 보이고 있습니다. 2025년 12억 5,000만 달러에서 2026년에는 13억 5,000만 달러로, CAGR 7.9%로 확대될 전망입니다. 지난 몇 년간의 성장은 듀센형 근이영양증 유병률 증가, 분자생물학 기술의 발전, 희귀 유전질환에 대한 인식 개선, 조기 진단 도구 개발, 학계와 제약사 간의 연구 협력 증가에 기인하는 것으로 보입니다.

듀센형 근이영양증 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 18억 7,000만 달러에 달하고, CAGR은 8.5%가 될 전망입니다. 예측 기간 동안 성장 요인으로는 유전자 치료 도입 확대, 정밀의료 접근법 확산, 희귀질환 치료제 개발 투자 증가, 희귀질환 치료제 규제 혜택, 환자 관리에 있어 디지털 헬스 솔루션의 통합 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 유전자 편집 기술의 발전, 맞춤형 치료 프로토콜의 확립, 희귀질환 연구 자금의 확대, 환자 중심 치료 모델, 오펀드럭 개발 등을 꼽을 수 있습니다.

만성질환의 유병률 증가는 향후 몇 년 동안 듀센형 근이영양증(DMD) 치료제 시장의 성장을 견인할 것으로 예상됩니다. 만성질환이란 증상이 최소 1년 이상 지속되는 장기적인 병태를 말합니다. 듀센형 근이영양증 치료제는 이 유전성 질환을 앓고 있는 환자들의 치료 요구에 부응하고, 만성질환의 관리와 잠재적 완화에 있어 맞춤형 의료의 중요성을 강조하고 있습니다. 예를 들어, 2023년 1월 미국 정부기관인 국립의학도서관이 발표한 보고서에 따르면, 2050년까지 50세 이상 미국인 중 적어도 한 가지 이상의 만성질환을 앓고 있는 사람의 수는 1억 4,266만 명에 달할 것으로 예측하고 있습니다. 따라서 만성질환의 증가 추세는 DMD 시장의 성장을 뒷받침하는 요인으로 작용하고 있습니다.

DMD 시장의 주요 기업들은 임상시험 설계와 같은 기술적 진보에 집중하여 의약품 개발의 효율성과 유효성 향상, 환자 결과 개선, 새로운 치료법 승인 가속화를 위해 노력하고 있습니다. 임상시험 설계란 새로운 치료법의 안전성-유효성을 평가하기 위한 시험 계획 및 조직화를 의미하며, 목적 설정, 피험자 선정, 방법론 및 분석 방법의 수립 등을 포함합니다. 예를 들어, 2024년 3월 미국 비영리단체인 크리티컬 패스 연구소(C-Path)는 'DMD 임상시험 시뮬레이터(CTS)'를 발표했습니다. C-Path의 Duchenne 근이영양증 규제과학 컨소시엄이 개발한 CTS는 DMD 치료제의 유효성 시험 설계를 최적화합니다. 기능 검사 결과의 고급 모델링, 다중 시나리오 시뮬레이션, 시험 설계 효율성 향상 등의 기능을 갖추고 있으며, C-Path 웹사이트와 희귀질환 치료 촉진 데이터 및 분석 플랫폼(RDCA-DAP)을 통해 일반에 공개되어 DMD 연구에 종사하는 연구자 및 제약사에게 유용한 도구로 활용되고 있습니다. 연구자 및 제약사에게 유용한 도구로 활용되고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의가 공급망에 미치는 영향, 코로나가 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계의 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 시장에서 세계의 총 잠재 시장 규모(TAM)

제9장 시장 세분화

제10장 지역별, 국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자 환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업과 혁신적 기업

제38장 세계의 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Duchenne muscular dystrophy is a genetic disorder that leads to progressive muscle loss, affecting skeletal, cardiac, and respiratory muscles. It is caused by a mutation in the gene responsible for producing dystrophin, a protein essential for proper muscle function.

The main therapeutic approaches for Duchenne muscular dystrophy include mutation suppression and the exon-skipping approach. Exon skipping is the most common form of alternative splicing, where introns and regions of pre-mRNA that normally function as exons are removed during the formation of the final mRNA. Therapeutic classes include molecular-based therapies and steroid therapy, administered via oral, parenteral, and other routes. These therapies are distributed through hospital pharmacies, online pharmacies, and retail pharmacies for end-users such as hospitals, homecare services, specialty clinics, and others.

Tariffs have impacted the duchenne muscular dystrophy market by increasing the cost of imported biologics, gene therapies, and specialized molecular compounds. These tariffs have slowed the supply of critical therapeutic components, particularly affecting molecular-based therapies and gene therapy segments in North America and Europe. While the higher costs pose challenges, they have encouraged local manufacturing and innovation in therapy delivery, potentially driving development of cost-optimized treatments for global markets.

The duchenne muscular dystrophy market research report is one of a series of new reports from The Business Research Company that provides duchenne muscular dystrophy market statistics, including duchenne muscular dystrophy industry global market size, regional shares, competitors with a duchenne muscular dystrophy market share, detailed duchenne muscular dystrophy market segments, market trends and opportunities, and any further data you may need to thrive in the duchenne muscular dystrophy industry. This duchenne muscular dystrophy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The duchenne muscular dystrophy market size has grown strongly in recent years. It will grow from $1.25 billion in 2025 to $1.35 billion in 2026 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to increasing prevalence of duchenne muscular dystrophy, advancements in molecular biology techniques, rising awareness about rare genetic disorders, development of early diagnostic tools, increasing research collaborations between academic and pharmaceutical institutions.

The duchenne muscular dystrophy market size is expected to see strong growth in the next few years. It will grow to $1.87 billion in 2030 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to growth in gene therapy adoption, expansion of precision medicine approaches, increased investment in rare disease drug development, regulatory incentives for orphan drugs, integration of digital health solutions in patient management. Major trends in the forecast period include gene editing advancements, personalized treatment protocols, rare disease research funding, patient-centric care models, orphan drug development.

The rising prevalence of chronic diseases is expected to drive growth in the Duchenne muscular dystrophy (DMD) market in the coming years. Chronic diseases are long-lasting conditions with symptoms that persist for at least a year. Duchenne muscular dystrophy addresses the therapeutic needs of individuals with this genetic disorder, highlighting the importance of personalized medicine in managing and potentially mitigating chronic conditions. For example, in January 2023, the National Library of Medicine, a US-based government agency, reported that the number of Americans aged 50 and older with at least one chronic condition is projected to reach 142.66 million by 2050. Therefore, the increasing prevalence of chronic diseases is supporting growth in the DMD market.

Key companies in the DMD market are focusing on technological advancements, such as clinical trial design, to improve the efficiency and effectiveness of drug development, enhance patient outcomes, and accelerate approval of new therapies. Clinical trial design involves planning and organizing trials to evaluate a new treatment's safety and efficacy, including defining objectives, selecting participants, and outlining methods and analyses. For instance, in March 2024, the Critical Path Institute (C-Path), a US-based non-profit organization, launched the DMD Clinical Trial Simulator (CTS). Developed by C-Path's Duchenne Regulatory Science Consortium, the CTS optimizes the design of efficacy studies for DMD therapies. Its features include advanced modeling of functional test performance, simulation of multiple scenarios, increased trial design efficiency, and public accessibility via the C-Path website and the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP), making it a valuable tool for researchers and pharmaceutical companies working on DMD.

In October 2025, Novartis AG, a Switzerland-based global pharmaceutical company, acquired Avidity Biosciences, Inc. for $12 billion in cash. This acquisition aims to expand Novartis's RNA-targeted therapy portfolio, strengthen its presence in genetic disease treatments, and enhance its capacity to develop innovative medicines for patients with serious and rare conditions. Avidity Biosciences, Inc., is a US-based biotechnology company developing del-zota, a treatment for Duchenne muscular dystrophy.

Major companies operating in the duchenne muscular dystrophy market are Pfizer Inc., GlaxoSmithKline plc, BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Asklepios BioPharmaceutical Inc., Catabasis Pharmaceuticals Inc., Wave Life Sciences Ltd., Bristol Myers Squibb Company, BridgeBio Pharma Inc., Rocket Pharmaceuticals Inc., Italfarmaco SpA, Solid Biosciences Inc., Avidity Biosciences Inc., Fulcrum Therapeutics Inc., Akashi Therapeutics Inc., Capricor Therapeutics Inc., Santhera Pharmaceuticals Holding, Armagen Technologies Inc., Dyne Therapeutics Inc., Benitec Biopharma Limited, Edgewise Therapeutics Inc., WAVE Life Sciences Ltd.

North America was the largest region in the Duchenne muscular dystrophy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global duchenne muscular dystrophy market during the forecast period. The regions covered in the duchenne muscular dystrophy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the duchenne muscular dystrophy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The duchenne muscular dystrophy market includes revenues earned by entities by providing respiratory therapy, physical therapy and gene therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Duchenne Muscular Dystrophy Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses duchenne muscular dystrophy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for duchenne muscular dystrophy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The duchenne muscular dystrophy market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Therapy: Mutation Suppression; Exon Skipping Approach
• 2) By Therapeutic Class: Molecular Based Therapies; Steroid Therapy
• 3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
• 4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
• 5) By End User: Hospitals; Homecare; Specialty Clinics; Other End-Users
• Subsegments:
• 1) By Mutation Suppression: Antisense Oligonucleotides (ASOs); Small Molecules; Gene Therapy
• 2) By Exon Skipping Approach: Exon-Skipping Therapies; Combination Therapies; Clinical Trials And Investigational Drugs
• Companies Mentioned: Pfizer Inc.; GlaxoSmithKline plc; BioMarin Pharmaceutical Inc.; Sarepta Therapeutics Inc.; PTC Therapeutics Inc.; Asklepios BioPharmaceutical Inc.; Catabasis Pharmaceuticals Inc.; Wave Life Sciences Ltd.; Bristol Myers Squibb Company; BridgeBio Pharma Inc.; Rocket Pharmaceuticals Inc.; Italfarmaco SpA; Solid Biosciences Inc.; Avidity Biosciences Inc.; Fulcrum Therapeutics Inc.; Akashi Therapeutics Inc.; Capricor Therapeutics Inc.; Santhera Pharmaceuticals Holding; Armagen Technologies Inc.; Dyne Therapeutics Inc.; Benitec Biopharma Limited; Edgewise Therapeutics Inc.; WAVE Life Sciences Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Duchenne Muscular Dystrophy Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Duchenne Muscular Dystrophy Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Duchenne Muscular Dystrophy Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Duchenne Muscular Dystrophy Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Gene Editing Advancements
  • 4.2.2 Personalized Treatment Protocols
  • 4.2.3 Rare Disease Research Funding
  • 4.2.4 Patient-Centric Care Models
  • 4.2.5 Orphan Drug Development

5. Duchenne Muscular Dystrophy Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Specialty Clinics
• 5.3 Homecare
• 5.4 Research Institutes
• 5.5 Rehabilitation Centers

6. Duchenne Muscular Dystrophy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Duchenne Muscular Dystrophy Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Duchenne Muscular Dystrophy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Duchenne Muscular Dystrophy Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Duchenne Muscular Dystrophy Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Duchenne Muscular Dystrophy Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Duchenne Muscular Dystrophy Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Duchenne Muscular Dystrophy Market Segmentation

• 9.1. Global Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Mutation Suppression, Exon Skipping Approach
• 9.2. Global Duchenne Muscular Dystrophy Market, Segmentation By Therapeutic Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Molecular Based Therapies, Steroid Therapy
• 9.3. Global Duchenne Muscular Dystrophy Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral, Parenteral, Other Routes Of Administration
• 9.4. Global Duchenne Muscular Dystrophy Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
• 9.5. Global Duchenne Muscular Dystrophy Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Homecare, Specialty Clinics, Other End-Users
• 9.6. Global Duchenne Muscular Dystrophy Market, Sub-Segmentation Of Mutation Suppression, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Antisense Oligonucleotides (ASOs), Small Molecules, Gene Therapy
• 9.7. Global Duchenne Muscular Dystrophy Market, Sub-Segmentation Of Exon Skipping Approach, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Exon-Skipping Therapies, Combination Therapies, Clinical Trials And Investigational Drugs

10. Duchenne Muscular Dystrophy Market Regional And Country Analysis

• 10.1. Global Duchenne Muscular Dystrophy Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Duchenne Muscular Dystrophy Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Duchenne Muscular Dystrophy Market

• 11.1. Asia-Pacific Duchenne Muscular Dystrophy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Duchenne Muscular Dystrophy Market

• 12.1. China Duchenne Muscular Dystrophy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Duchenne Muscular Dystrophy Market

• 13.1. India Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Duchenne Muscular Dystrophy Market

• 14.1. Japan Duchenne Muscular Dystrophy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Duchenne Muscular Dystrophy Market

• 15.1. Australia Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Duchenne Muscular Dystrophy Market

• 16.1. Indonesia Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Duchenne Muscular Dystrophy Market

• 17.1. South Korea Duchenne Muscular Dystrophy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Duchenne Muscular Dystrophy Market

• 18.1. Taiwan Duchenne Muscular Dystrophy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Duchenne Muscular Dystrophy Market

• 19.1. South East Asia Duchenne Muscular Dystrophy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Duchenne Muscular Dystrophy Market

• 20.1. Western Europe Duchenne Muscular Dystrophy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Duchenne Muscular Dystrophy Market

• 21.1. UK Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Duchenne Muscular Dystrophy Market

• 22.1. Germany Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Duchenne Muscular Dystrophy Market

• 23.1. France Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Duchenne Muscular Dystrophy Market

• 24.1. Italy Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Duchenne Muscular Dystrophy Market

• 25.1. Spain Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Duchenne Muscular Dystrophy Market

• 26.1. Eastern Europe Duchenne Muscular Dystrophy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Duchenne Muscular Dystrophy Market

• 27.1. Russia Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Duchenne Muscular Dystrophy Market

• 28.1. North America Duchenne Muscular Dystrophy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Duchenne Muscular Dystrophy Market

• 29.1. USA Duchenne Muscular Dystrophy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Duchenne Muscular Dystrophy Market

• 30.1. Canada Duchenne Muscular Dystrophy Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Duchenne Muscular Dystrophy Market

• 31.1. South America Duchenne Muscular Dystrophy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Duchenne Muscular Dystrophy Market

• 32.1. Brazil Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Duchenne Muscular Dystrophy Market

• 33.1. Middle East Duchenne Muscular Dystrophy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Duchenne Muscular Dystrophy Market

• 34.1. Africa Duchenne Muscular Dystrophy Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Duchenne Muscular Dystrophy Market, Segmentation By Therapy, Segmentation By Therapeutic Class, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Duchenne Muscular Dystrophy Market Regulatory and Investment Landscape

36. Duchenne Muscular Dystrophy Market Competitive Landscape And Company Profiles

• 36.1. Duchenne Muscular Dystrophy Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Duchenne Muscular Dystrophy Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Duchenne Muscular Dystrophy Market Company Profiles
  • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. BioMarin Pharmaceutical Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Sarepta Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. PTC Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Duchenne Muscular Dystrophy Market Other Major And Innovative Companies

• Asklepios BioPharmaceutical Inc., Catabasis Pharmaceuticals Inc., Wave Life Sciences Ltd., Bristol Myers Squibb Company, BridgeBio Pharma Inc., Rocket Pharmaceuticals Inc., Italfarmaco SpA, Solid Biosciences Inc., Avidity Biosciences Inc., Fulcrum Therapeutics Inc., Akashi Therapeutics Inc., Capricor Therapeutics Inc., Santhera Pharmaceuticals Holding, Armagen Technologies Inc., Dyne Therapeutics Inc.

38. Global Duchenne Muscular Dystrophy Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Duchenne Muscular Dystrophy Market

40. Duchenne Muscular Dystrophy Market High Potential Countries, Segments and Strategies

• 40.1 Duchenne Muscular Dystrophy Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Duchenne Muscular Dystrophy Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Duchenne Muscular Dystrophy Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer